These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 35451945

  • 1. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA, Lob SH, Khan A, Chen WT, Woo PCY, Seto WH, Ip M, Leung S, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [Abstract] [Full Text] [Related]

  • 2. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015.
    Castanheira M, Duncan LR, Mendes RE, Sader HS, Shortridge D.
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073
    [Abstract] [Full Text] [Related]

  • 3. Activity of ceftolozane/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections - SMART United States 2018-2019.
    Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.
    BMC Microbiol; 2021 Mar 06; 21(1):74. PubMed ID: 33676406
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020.
    Karlowsky JA, Lob SH, Siddiqui F, Akrich B, DeRyke CA, Young K, Motyl MR, Hawser SP, Sahm DF.
    J Med Microbiol; 2023 Feb 06; 72(2):. PubMed ID: 36763081
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of ceftolozane/tazobactam against Gram-negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries-SMART 2017-2019.
    Lob SH, Kazmierczak KM, Chen WT, Siddiqui F, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Glob Antimicrob Resist; 2022 Jun 06; 29():527-533. PubMed ID: 34896336
    [Abstract] [Full Text] [Related]

  • 6. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS, Mendes RE, Arends SJR, Carvalhaes CG, Shortridge D, Castanheira M.
    Int J Antimicrob Agents; 2023 Apr 06; 61(4):106744. PubMed ID: 36738849
    [Abstract] [Full Text] [Related]

  • 7. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS, Castanheira M, Duncan LR, Mendes RE.
    Int J Infect Dis; 2021 Dec 06; 113():279-281. PubMed ID: 34670144
    [Abstract] [Full Text] [Related]

  • 8. Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
    Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.
    J Glob Antimicrob Resist; 2020 Mar 06; 20():209-213. PubMed ID: 31351246
    [Abstract] [Full Text] [Related]

  • 9. Antimicrobial Activity of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Comparators Tested Against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States Medical Centers in 2016-2018.
    Sader HS, Carvalhaes CG, Streit JM, Doyle TB, Castanheira M.
    Microb Drug Resist; 2021 Mar 06; 27(3):342-349. PubMed ID: 32762605
    [Abstract] [Full Text] [Related]

  • 10. Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017-2020.
    Karlowsky JA, Lob SH, Khan TK, Chen WT, Woo PCY, Seto WH, Ip M, Leung SWM, Wong QW, Chau RWY, DeRyke CA, Young K, Motyl MR, Sahm DF.
    J Glob Antimicrob Resist; 2023 Jun 06; 33():260-266. PubMed ID: 37086892
    [Abstract] [Full Text] [Related]

  • 11. Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)-SMART 2017-21.
    Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF.
    JAC Antimicrob Resist; 2023 Aug 06; 5(4):dlad098. PubMed ID: 37577157
    [Abstract] [Full Text] [Related]

  • 12. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

  • 13. ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime.
    Jacobs MR, Abdelhamed AM, Good CE, Mack AR, Bethel CR, Marshall S, Hujer AM, Hujer KM, Patel R, van Duin D, Fowler VG, Rhoads DD, Six DA, Moeck G, Uehara T, Papp-Wallace KM, Bonomo RA.
    Antimicrob Agents Chemother; 2024 Sep 04; 68(9):e0075124. PubMed ID: 39133021
    [Abstract] [Full Text] [Related]

  • 14. Susceptibility of Gram-negative pathogens collected in Israel to ceftolozane/tazobactam, imipenem/relebactam and comparators: SMART 2018-22.
    Wise MG, DeRyke CA, Alekseeva I, Siddiqui F, Young K, Motyl MR, Sahm DF.
    JAC Antimicrob Resist; 2024 Oct 04; 6(5):dlae150. PubMed ID: 39291180
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018).
    Cantón R, Loza E, Arcay RM, Cercenado E, Castillo FJ, Cisterna R, Gálvez-Benítez L, González Romo F, Hernández-Cabezas A, Rodríguez-Lozano J, Suárez-Barrenechea AI, Tubau F, Díaz-Regañón J, López-Mendoza D, SMART-Spain Working Group.
    Rev Esp Quimioter; 2021 Jun 04; 34(3):228-237. PubMed ID: 33645948
    [Abstract] [Full Text] [Related]

  • 16. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Castanheira M, Flamm RK.
    Int J Antimicrob Agents; 2018 Feb 04; 51(2):181-189. PubMed ID: 28993143
    [Abstract] [Full Text] [Related]

  • 17. In vitro activity of ceftolozane/tazobactam against phenotypically defined extended-spectrum β-lactamase (ESBL)-positive isolates of Escherichia coli and Klebsiella pneumoniae isolated from hospitalized patients (SMART 2016).
    Karlowsky JA, Kazmierczak KM, Young K, Motyl MR, Sahm DF.
    Diagn Microbiol Infect Dis; 2020 Apr 04; 96(4):114925. PubMed ID: 31954597
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against clinical isolates of meropenem-non-susceptible Pseudomonas aeruginosa: A two-centre study.
    Mirza HC, Hortaç E, Koçak AA, Demirkaya MH, Yayla B, Güçlü AÜ, Başustaoğlu A.
    J Glob Antimicrob Resist; 2020 Mar 04; 20():334-338. PubMed ID: 31568882
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial activity of high-dose cefepime-tazobactam (WCK 4282) against a large collection of gram-negative organisms collected worldwide in 2018 and 2019.
    Sader HS, Carvalhaes CG, Mendes RE, Castanheira M.
    Int J Infect Dis; 2022 Mar 04; 116():306-312. PubMed ID: 35066163
    [Abstract] [Full Text] [Related]

  • 20. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
    Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I.
    Int J Infect Dis; 2017 Sep 04; 62():39-43. PubMed ID: 28610832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.